Suppr超能文献

含截尾数据的平均成本效益比。

Average cost-effectiveness ratio with censored data.

作者信息

Bang Heejung, Zhao Hongwei

机构信息

Division of Biostatistics, Department of Public Health Sciences, University of California, Davis, California, USA.

出版信息

J Biopharm Stat. 2012;22(2):401-15. doi: 10.1080/10543406.2010.544437.

Abstract

In cost-effectiveness analysis, interest could lie foremost in the incremental cost-effectiveness ratio (ICER), which is the ratio of the incremental cost to the incremental benefit of two competing interventions. The average cost-effectiveness ratio (ACER) is the ratio of the cost to benefit of an intervention without reference to a comparator. A vast literature is available for statistical inference of the ICERs, but limited methods have been developed for the ACERs, particularly in the presence of censoring. Censoring is a common feature in prospective studies, and valid analyses should properly adjust for censoring in cost as well as in effectiveness. In this article, we propose statistical methods for constructing a confidence interval for the ACER from censored data. Different methods-Fieller, Taylor, bootstrap-are proposed, and through simulation studies and data analysis, we address the performance characteristics of these methods.

摘要

在成本效益分析中,人们可能首先关注增量成本效益比(ICER),它是两种相互竞争干预措施的增量成本与增量效益之比。平均成本效益比(ACER)是一项干预措施的成本与效益之比,不涉及比较对象。关于ICER的统计推断已有大量文献,但针对ACER的方法开发有限,尤其是在存在删失的情况下。删失是前瞻性研究的一个常见特征,有效的分析应在成本和效益方面对删失进行适当调整。在本文中,我们提出了从删失数据构建ACER置信区间的统计方法。我们提出了不同的方法——菲勒方法、泰勒方法、自助法——并通过模拟研究和数据分析,探讨了这些方法的性能特征。

相似文献

1
Average cost-effectiveness ratio with censored data.
J Biopharm Stat. 2012;22(2):401-15. doi: 10.1080/10543406.2010.544437.
2
A study on confidence intervals for incremental cost-effectiveness ratios.
Biom J. 2008 Aug;50(4):505-14. doi: 10.1002/bimj.200810439.
6
A note on the estimation of confidence intervals for cost-effectiveness when costs and effects are censored.
Med Decis Making. 2002 Mar-Apr;22(2):173-7. doi: 10.1177/0272989X0202200214.
7
Nonparametric statistical methods for cost-effectiveness analyses.
Biometrics. 2006 Jun;62(2):576-88. doi: 10.1111/j.1541-0420.2006.00509.x.
8
Nonparametric inference for time-dependent incremental cost-effectiveness ratios.
Stat Med. 2015 Dec 30;34(30):4057-69. doi: 10.1002/sim.6594. Epub 2015 Jul 27.
9
Nonparametric inference for median costs with censored data.
Biometrics. 2012 Sep;68(3):717-25. doi: 10.1111/j.1541-0420.2012.01755.x. Epub 2012 Feb 24.
10
Bootstrap confidence intervals for medical costs with censored observations.
Stat Med. 2004 Nov 15;23(21):3365-76. doi: 10.1002/sim.1556.

引用本文的文献

1
"Patient-Specific" Cost and Quality Value Comparison of Endoscopic Carpal Tunnel Release in Two Surgical Settings.
J Hand Surg Glob Online. 2025 Aug 13;7(5):100802. doi: 10.1016/j.jhsg.2025.100802. eCollection 2025 Sep.
2
Cost effectiveness and return on investment analysis for surgical care in a conflict-affected region of Sudan.
PLOS Glob Public Health. 2024 Nov 4;4(11):e0003712. doi: 10.1371/journal.pgph.0003712. eCollection 2024.
3
Pharmacoeconomics of medicines used for geriatric individuals in a tertiary care hospital in Delhi.
Indian J Med Res. 2024 Feb 1;159(2):143-152. doi: 10.4103/ijmr.ijmr_2507_21. Epub 2024 Apr 4.
4
Breast Cancer Screening Should Embrace Precision Medicine: Evidence by Reviewing Economic Evaluations in China.
Adv Ther. 2023 Apr;40(4):1393-1417. doi: 10.1007/s12325-023-02450-z. Epub 2023 Feb 17.
10
A comparative study of aceclofenac versus etoricoxib in the management of acute low back pain in a tertiary care hospital.
J Drug Assess. 2020 Mar 31;9(1):60-65. doi: 10.1080/21556660.2020.1734008. eCollection 2020.

本文引用的文献

1
The Kaplan-Meier Estimator as an Inverse-Probability-of-Censoring Weighted Average.
Am Stat. 2001;55(3):207-210. doi: 10.1198/000313001317098185. Epub 2012 Jan 1.
2
Cost analysis with censored data.
Med Care. 2009 Jul;47(7 Suppl 1):S115-9. doi: 10.1097/MLR.0b013e31819bc08a.
3
A study on confidence intervals for incremental cost-effectiveness ratios.
Biom J. 2008 Aug;50(4):505-14. doi: 10.1002/bimj.200810439.
4
A clinician's guide to correct cost-effectiveness analysis: think incremental not average.
Can J Psychiatry. 2008 Apr;53(4):267-74. doi: 10.1177/070674370805300408.
5
On the equivalence of some medical cost estimators with censored data.
Stat Med. 2007 Oct 30;26(24):4520-30. doi: 10.1002/sim.2882.
6
Information created to evade reality (ICER): things we should not look to for answers.
Pharmacoeconomics. 2006;24(11):1121-31. doi: 10.2165/00019053-200624110-00008.
7
Nonparametric statistical methods for cost-effectiveness analyses.
Biometrics. 2006 Jun;62(2):576-88. doi: 10.1111/j.1541-0420.2006.00509.x.
8
Incremental cost-effectiveness ratios (ICERs): the silence of the lambda.
Soc Sci Med. 2006 May;62(9):2091-100. doi: 10.1016/j.socscimed.2005.10.023. Epub 2005 Dec 1.
9
Medical cost analysis: application to colorectal cancer data from the SEER Medicare database.
Contemp Clin Trials. 2005 Oct;26(5):586-97. doi: 10.1016/j.cct.2005.05.004.

文献AI研究员

20分钟写一篇综述,助力文献阅读效率提升50倍。

立即体验

用中文搜PubMed

大模型驱动的PubMed中文搜索引擎

马上搜索

文档翻译

学术文献翻译模型,支持多种主流文档格式。

立即体验